Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Medical Oncology (Northwood, London, England)|January 23, 2019
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicityIgal Kushnir, Kim Koczka, Michael Ong, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|February 11, 2010
Scientific overview of the CSCI-CITAC 2009 conferenceStephan Ong Tone, Sagar Dugani, Harry Marshall, et al.
Cancers|June 27, 2024
Real-World Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization, and Costs in Advanced Hepatocellular Carcinoma in Ontario, CanadaSoo Jin Seung, Hasnain Saherawala, YongJin Kim, et al.
Annals of Surgical Oncology|May 5, 2020
Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at RecurrenceAndrea Marie Ibrahim, Melanie Le May, Dominick Bossé, et al.
Annals of Surgical Oncology|May 24, 2020
Correction to: Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at RecurrenceAndrea Marie Ibrahim, Melanie Le May, Dominick Bossé, et al.
Critical Reviews in Oncology/Hematology|February 23, 2020
A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive ModelDavid J Stewart, Dominick Bossé, Glenwood Goss, et al.
Current Oncology (Toronto, Ont.)|January 24, 2025
Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer TherapyJennifer Leigh, Ranjeeta Mallick, Stephanie Brule, et al.
Critical Care Medicine|February 15, 2011
Total liquid ventilation efficacy in an ovine model of severe meconium aspiration syndromeOlivier Avoine, Dominick Bossé, Benoit Beaudry, et al.
Neurology. Clinical Practice|May 7, 2025
Malignancy Workup in Cryptogenic Stroke: A Survey of Canadian Stroke and Thrombosis ExpertsLaurence Poirier, Deborah M Siegal, Dominick Bossé, et al.
Cancer|December 22, 2017
Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysisLauren C Harshman, Wanling Xie, Raphael B Moreira, et al.
Pageof 5